BIMI International Medical Inc.
BIMI News Today: Stay Updated with the Latest BIMI International Medical Inc. News in Real Time
Find BIMI news now at Meyka AI. Stay informed with the latest BIMI International Medical Inc. stocks updates, including price news, market analysis, and expert insights.
4259.T ExaWizards Inc. at JPY 707 on 24 Feb 2026: AI growth vs high valuation
4259.T stock update: ExaWizards at JPY 707 on 24 Feb 2026 with Meyka AI forecasts and valuation signals
FTI.PA stock: TechnipFMC pre-market most active 24 Feb 2026, heavy volume
Pre-market update: FTI.PA stock at €5.91 with heavy volume; grade, valuation and model forecast included
RENOVA 9519.T down 6.49% intraday on JPX: volume up, watch JPY 750 support
Intraday: 9519.T stock at JPY 771.00, down 6.49% with volume surge; technical, valuation and Meyka AI forecast inside
INR 7.00 pre-market: LONGSPUR.BO stock shows oversold bounce with 20.00% upside
Pre-market look at LONGSPUR.BO stock at INR 7.00; oversold bounce signals and a 20.00% price target
^GSPC Today, February 23: Spanberger SOTU Reply Puts Health Costs in Focus
Abigail Spanberger SOTU ponse puts US healthcare costs in focus. What it could mean for ^GSPC levels, risk sentiment, and UK portfolios, with key technicals and 2026 midterms context.
ABT.SW Abbott Laboratories (SIX) down 13.50% pre-market: CHF86.50 support to watch
Pre-market: ABT.SW stock falls 13.50% to CHF86.50 on 24 Feb 2026; oversold technicals and Meyka AI projects CHF100.56 target
VisionSys AI (0T8B.F XETRA) -37.50% pre-market 24 Feb 2026: liquidity
Pre-market update on 0T8B.F stock: down 37.50% to €0.05 on XETRA with low liquidity and weak fundamentals
CNQ.TO Canadian Natural (TSX) C$58.02 close 23 Feb 2026: Most active, see Meyka
CNQ.TO stock closed C$58.02 on 23 Feb 2026 with 13.47M shares; technicals overbought and Meyka forecast shows downside
UNH Stock Today: February 23 — Weak 2026 Outlook Spurs Target Cuts
UNH stock drops as 2026 revenue guidance runs about $15B below Street and Mizuho, Truist cut analyst price targets. Policy risk rises with near flat 2027 Medicare Advantage rates.